17 September 2021: Clinical Research
Factors Associated with Recurrence of Hepatocellular Carcinoma in 197 Patients Following Transarterial Chemoembolization: A Retrospective Study from a Single Center
Hongsheng Zhang 1ABCE* , Xiaodong Zhao 2AEF , Wenhai Yu 1BCDOI: 10.12659/MSM.929879
Med Sci Monit 2021; 27:e929879
Table 1 Baseline clinicopathological characteristics.
| Characteristics, n (%) | Total (n=197) | Non-ER group (n=66) | ER group (n=131) |
|---|---|---|---|
| Sex | |||
| Male | 167 (84.77) | 53 (80.30) | 114 (87.02) |
| Female | 30 (15.23) | 13 (19.70) | 17 (12.98) |
| Age, years, (χ̄±s) | 58.81±8.74 | 59.26±8.47 | 58.59±8.90 |
| BMI, kg/m | |||
| 98 (49.75) | 22 (33.33) | 76 (58.02) | |
| ≥23.9 | 99 (50.25) | 44 (66.67) | 55 (41.98) |
| Maximum tumor diameter, cm, M(Q1,Q3) | 5.90 (3.30, 9.20) | 3.45 (2.50, 4.70) | 7.20 (4.80, 11.00) |
| Adjacent lobe invasion | |||
| No | 118 (59.90) | 61 (92.42) | 57 (43.51) |
| Yes | 79 (40.10) | 5 (7.58) | 74 (56.49) |
| Extrathoracic metastasis | |||
| No | 191 (96.95) | 66 (100.00) | 125 (95.42) |
| Yes | 6 (3.05) | 0 (0.00) | 6 (4.58) |
| Vascular invasion | |||
| No | 172 (87.31) | 66 (100.00) | 106 (80.92) |
| Yes | 25 (12.69) | 0 (0.00) | 25 (19.08) |
| Lymph node metastasis | |||
| No | 181 (91.88) | 65 (98.48) | 116 (88.55) |
| Yes | 16 (8.12) | 1 (1.52) | 15 (11.45) |
| Child-pugh score | |||
| A | 153 (77.66) | 63 (95.45) | 90 (68.70) |
| B | 42 (21.32) | 3 (4.55) | 39 (29.77) |
| C | 2 (1.02) | 0 (0.00) | 2 (1.53) |
| BCLC staging | |||
| Very early/early stage | 64 (32.49) | 46 (69.70) | 18 (13.74) |
| Intermediate stage | 99 (50.25) | 20 (30.30) | 79 (60.31) |
| Advanced/end stage | 34 (17.26) | 0 (0.00) | 34 (25.95) |
| Follow-up time, months, M (Q1, Q3) | 20.36 (9.08, 23.51) | 23.74 (22.79, 24.75) | 11.80 (6.52, 20.36) |
| ER – early recurrence; BMI – body mass index; BCLC staging – Barcelona clinic liver cancer staging. | |||